|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
|
ES2828739T3
(es)
|
2006-04-07 |
2021-05-27 |
Aerpio Pharmaceuticals Inc |
Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos
|
|
WO2009114085A2
(en)
|
2008-03-03 |
2009-09-17 |
The University Of Miami |
Allogeneic cancer cell-based immunotherapy
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
IN2015DN02826A
(enExample)
|
2009-09-03 |
2015-09-11 |
Merck Sharp & Dohme |
|
|
EP2504028A4
(en)
*
|
2009-11-24 |
2014-04-09 |
Amplimmune Inc |
SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
|
|
US8993524B2
(en)
|
2010-03-05 |
2015-03-31 |
The Johns Hopkins University |
Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
|
|
EP3252076B1
(en)
|
2011-01-14 |
2019-09-04 |
The Regents Of The University Of California |
Diagnostic use of antibodies against ror-1 protein
|
|
WO2012123755A1
(en)
|
2011-03-17 |
2012-09-20 |
The University Of Birmingham |
Re-directed immunotherapy
|
|
JP6047142B2
(ja)
*
|
2011-04-01 |
2016-12-21 |
ウニヴェルズィテート シュトゥットガルト |
抗体結合ドメインを有する組換えｔｎｆリガンドファミリーメンバーポリペプチドおよびそれらの使用
|
|
RU2661764C2
(ru)
|
2011-05-27 |
2018-07-19 |
Эббви Байотекнолоджи Лтд., |
Композиции и способы на основе dac hyp
|
|
MX363351B
(es)
|
2011-10-13 |
2019-03-20 |
Aerpio Therapeutics Inc |
Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular.
|
|
ES2918580T3
(es)
*
|
2011-10-17 |
2022-07-19 |
Io Biotech Aps |
Inmunoterapia basada en PD-L1
|
|
AU2013216863B2
(en)
*
|
2012-02-10 |
2018-09-06 |
Seagen Inc. |
Detection and treatment of CD30+ cancers
|
|
PE20150605A1
(es)
|
2012-04-27 |
2015-05-28 |
Cytomx Therapeutics Inc |
Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
|
|
PL3489254T3
(pl)
*
|
2012-04-30 |
2023-01-30 |
Biocon Limited |
Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
|
|
RU2692773C2
(ru)
|
2012-11-30 |
2019-06-27 |
Ф.Хоффманн-Ля Рош Аг |
Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
|
|
WO2015116178A1
(en)
*
|
2014-01-31 |
2015-08-06 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector t cells
|
|
EP2951199A4
(en)
|
2013-01-31 |
2016-07-20 |
Univ Jefferson |
Fusion proteins for the modulation of regulatory and effector T cells
|
|
EP2951209A4
(en)
|
2013-01-31 |
2016-06-22 |
Univ Jefferson |
CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF
|
|
EP2950814A4
(en)
|
2013-01-31 |
2016-06-08 |
Univ Jefferson |
FUSION PROTEINS BASED ON PD-L1 AND PD-L2 AND USES THEREOF
|
|
JP6367836B2
(ja)
|
2013-02-07 |
2018-08-01 |
ザ ジェネラル ホスピタル コーポレイション |
Ｔ制御性細胞の増殖または枯渇方法
|
|
MY186864A
(en)
*
|
2013-03-12 |
2021-08-26 |
Biocon Ltd |
Fusion immunomodulatory proteins and methods for making same
|
|
MX365567B
(es)
|
2013-03-13 |
2019-06-07 |
Genentech Inc |
Formulaciones de anticuerpo.
|
|
WO2014168715A1
(en)
*
|
2013-04-08 |
2014-10-16 |
R-Pharm Overseas, Inc. |
B7 ligands/cd20 inhibitor composition and use thereof
|
|
EP2986306A4
(en)
|
2013-04-18 |
2016-12-07 |
Armo Biosciences Inc |
METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING
|
|
JP6693872B2
(ja)
|
2013-07-25 |
2020-05-13 |
シトムクス セラピューティクス，インコーポレイティド |
多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
|
|
HK1225742A1
(zh)
*
|
2013-08-22 |
2017-09-15 |
Acceleron Pharma, Inc. |
TGF-β受体II型变体及其用途
|
|
US9540440B2
(en)
|
2013-10-30 |
2017-01-10 |
Cytomx Therapeutics, Inc. |
Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
|
|
KR20160079114A
(ko)
*
|
2013-11-11 |
2016-07-05 |
아르모 바이오사이언시스 인코포레이티드 |
질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
|
|
WO2015089283A1
(en)
|
2013-12-11 |
2015-06-18 |
Cytomx Therapeutics, Inc. |
Antibodies that bind activatable antibodies and methods of use thereof
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
US11213583B2
(en)
*
|
2014-02-05 |
2022-01-04 |
Cedars-Sinai Medical Center |
Methods and compositions for treating cancer and infectious diseases
|
|
HRP20210977T1
(hr)
|
2014-02-10 |
2021-09-17 |
Merck Patent Gmbh |
Ciljano inhibiranje tgf beta
|
|
US20170165364A1
(en)
*
|
2014-02-21 |
2017-06-15 |
Idac Theranostics, Inc. |
Therapeutic agent for solid cancer
|
|
AU2015222917A1
(en)
|
2014-02-27 |
2016-09-15 |
Lycera Corporation |
Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
|
|
EA201691765A1
(ru)
|
2014-03-14 |
2016-12-30 |
Новартис Аг |
Молекулы антител против lag-3 и их применения
|
|
US20150307620A1
(en)
*
|
2014-04-16 |
2015-10-29 |
University Of Connecticut |
Linked immunotherapeutic agonists that costimulate multiple pathways
|
|
WO2015171558A2
(en)
|
2014-05-05 |
2015-11-12 |
Lycera Corporation |
BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
|
|
EP3140291A4
(en)
|
2014-05-05 |
2018-01-10 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
|
|
CN103965364B
(zh)
*
|
2014-05-19 |
2016-06-08 |
亚飞（上海）生物医药科技有限公司 |
一种人源pdl2hsa系列融合蛋白及其制备与应用
|
|
WO2015178746A1
(ko)
*
|
2014-05-23 |
2015-11-26 |
주식회사 제넥신 |
Pd-l1 융합 단백질 및 이의 용도
|
|
LT3148579T
(lt)
|
2014-05-28 |
2021-05-25 |
Agenus Inc. |
Anti-gitr antikūnai ir jų panaudojimo būdai
|
|
PL3151921T3
(pl)
|
2014-06-06 |
2020-02-28 |
Bristol-Myers Squibb Company |
Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
|
|
ES2818800T3
(es)
*
|
2014-06-11 |
2021-04-14 |
Idac Theranostics Inc |
Método para reducir los efectos secundarios de un agente de control del punto de control inmunitario
|
|
KR102493543B1
(ko)
*
|
2014-07-21 |
2023-01-30 |
데리니아, 인크. |
자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
|
|
CA2955947A1
(en)
|
2014-07-25 |
2016-01-28 |
Cytomx Therapeutics, Inc. |
Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
|
|
JP6640834B2
(ja)
|
2014-08-11 |
2020-02-05 |
デリニア， インコーポレイテッド |
自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
|
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
ES2949173T3
(es)
|
2014-09-15 |
2023-09-26 |
Hoffmann La Roche |
Formulaciones de anticuerpo
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
ES2788979T3
(es)
|
2014-11-14 |
2020-10-23 |
Hoffmann La Roche |
Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF
|
|
WO2016118577A1
(en)
*
|
2015-01-22 |
2016-07-28 |
Medimmune, Llc |
Thymosin-beta-four fusion proteins
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
US11318163B2
(en)
|
2015-02-18 |
2022-05-03 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11596652B2
(en)
|
2015-02-18 |
2023-03-07 |
Enlivex Therapeutics R&D Ltd |
Early apoptotic cells for use in treating sepsis
|
|
US11497767B2
(en)
|
2015-02-18 |
2022-11-15 |
Enlivex Therapeutics R&D Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11000548B2
(en)
|
2015-02-18 |
2021-05-11 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11304976B2
(en)
|
2015-02-18 |
2022-04-19 |
Enlivex Therapeutics Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
US11512289B2
(en)
|
2015-02-18 |
2022-11-29 |
Enlivex Therapeutics Rdo Ltd |
Combination immune therapy and cytokine control therapy for cancer treatment
|
|
WO2016142532A1
(en)
*
|
2015-03-11 |
2016-09-15 |
Cellectis |
Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients
|
|
MA42971A
(fr)
|
2015-03-13 |
2018-08-15 |
Cytomx Therapeutics Inc |
Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
|
|
JP6996979B2
(ja)
|
2015-03-31 |
2022-02-04 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
三量体ｔｎｆファミリーリガンドを含む抗原結合分子
|
|
US11215616B2
(en)
|
2015-04-10 |
2022-01-04 |
National Institutes Of Health (Nih), (Dhhs), U.S. Government |
Methods of determining patient populations amenable to immunomodulatory treatment of cancer
|
|
SMT202100467T1
(it)
|
2015-04-17 |
2021-09-14 |
Alpine Immune Sciences Inc |
Proteine immunomodulatorie con affinità regolabili
|
|
JP6803339B2
(ja)
|
2015-04-21 |
2020-12-23 |
エンリヴェックス セラピューティクス リミテッド |
治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
|
|
RU2727165C2
(ru)
*
|
2015-05-04 |
2020-07-21 |
ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ |
Слитый полипептид с противораковой активностью
|
|
WO2016179343A1
(en)
|
2015-05-05 |
2016-11-10 |
Lycera Corporation |
DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
|
|
EP3292152A1
(en)
|
2015-05-07 |
2018-03-14 |
Agenus Inc. |
Anti-ox40 antibodies and methods of use thereof
|
|
DK3447075T3
(da)
|
2015-05-15 |
2023-11-13 |
Massachusetts Gen Hospital |
Antagonistiske antistoffer af antitumornekrosefaktorreceptor-superfamilien
|
|
EP3304079B1
(en)
|
2015-06-03 |
2020-06-03 |
Bristol-Myers Squibb Company |
Anti-gitr antibodies for cancer diagnostics
|
|
CN107980042B
(zh)
|
2015-06-11 |
2021-10-08 |
莱斯拉公司 |
用作RORγ激动剂和用于治疗疾病的芳基二氢-2H-苯并[b][1,4]噁嗪磺酰胺和相关化合物
|
|
MX383464B
(es)
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
CA2991628C
(en)
|
2015-07-16 |
2020-04-07 |
Bioxcel Therapeutics, Inc. |
A novel approach for treatment of cancer using immunomodulation
|
|
MX2017016844A
(es)
|
2015-07-16 |
2018-08-15 |
Biokine Therapeutics Ltd |
Composiciones y procedimientos para tratar cancer.
|
|
US11466093B2
(en)
|
2015-07-27 |
2022-10-11 |
The General Hospital Corporation |
Antibody derivatives with conditionally enabled effector function
|
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
|
WO2017024171A1
(en)
|
2015-08-04 |
2017-02-09 |
Acceleron Pharma Inc. |
Methods for treating myeloproliferative disorders
|
|
CA2995120A1
(en)
|
2015-08-25 |
2017-03-02 |
Armo Biosciences, Inc. |
Methods of using interleukin-10 for treating diseases and disorders
|
|
WO2017040312A1
(en)
|
2015-08-28 |
2017-03-09 |
The General Hospital Corporation |
Agonistic anti-tumor necrosis factor receptor 2 antibodies
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
US20200231652A1
(en)
|
2015-08-31 |
2020-07-23 |
National Research Council Of Canada |
Tgf-b-receptor ectodomain fusion molecules and uses thereof
|
|
CA2998589A1
(en)
*
|
2015-09-14 |
2017-03-23 |
Compass Therapeutics Llc |
Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-.beta.
|
|
SG10201913573UA
(en)
|
2015-10-01 |
2020-03-30 |
Heat Biologics Inc |
Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
MY206406A
(en)
|
2015-10-02 |
2024-12-16 |
Hoffmann La Roche |
Bispecific antibodies specific for a costimulatory tnf receptor
|
|
MA43028B1
(fr)
|
2015-10-02 |
2021-09-30 |
Hoffmann La Roche |
Anticorps bispécifiques pour pd1 et tim3
|
|
US20170107510A1
(en)
*
|
2015-10-14 |
2017-04-20 |
Batu Biologics, Inc. |
Dna nanoparticle based checkpoint inhibitors
|
|
WO2017075537A1
(en)
|
2015-10-30 |
2017-05-04 |
Aleta Biotherapeutics Inc. |
Compositions and methods for treatment of cancer
|
|
MA43134A
(fr)
|
2015-10-30 |
2018-09-05 |
Aleta Biotherapeutics Inc |
Compositions et méthodes de transduction tumorale
|
|
WO2017087784A1
(en)
*
|
2015-11-18 |
2017-05-26 |
Duke University |
Tumor infiltrating lymphocytes for treatment of cancer
|
|
MX2018006072A
(es)
|
2015-11-19 |
2018-08-01 |
Squibb Bristol Myers Co |
Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
|
|
WO2017096179A1
(en)
|
2015-12-02 |
2017-06-08 |
Agenus Inc. |
Antibodies and methods of use thereof
|
|
BR112018012352A2
(pt)
|
2015-12-16 |
2018-12-11 |
Merck Sharp & Dohme Corp. |
anticorpos anti-lag3 e fragmentos de ligação ao antígeno
|
|
CN108495651A
(zh)
|
2015-12-17 |
2018-09-04 |
诺华股份有限公司 |
抗pd-1的抗体分子及其用途
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
AU2017211247B2
(en)
*
|
2016-01-25 |
2023-03-09 |
Sanofi |
Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker
|
|
WO2017134592A1
(en)
*
|
2016-02-03 |
2017-08-10 |
Biocon Limited |
Anti-cd20/immunomodulatory fusion proteins and methods for making same
|
|
JP6884155B2
(ja)
|
2016-02-18 |
2021-06-09 |
エンリヴェックス セラピューティクス リミテッド |
癌治療のための併用免疫療法及びサイトカイン制御療法
|
|
US11542332B2
(en)
|
2016-03-26 |
2023-01-03 |
Bioatla, Inc. |
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
|
AU2017248830B2
(en)
|
2016-04-15 |
2023-03-09 |
Alpine Immune Sciences, Inc. |
CD80 variant immunomodulatory proteins and uses thereof
|
|
KR20250007678A
(ko)
*
|
2016-05-13 |
2025-01-14 |
더 제너럴 하스피탈 코포레이션 |
길항성 항-종양 괴사 인자 수용체 슈퍼패밀리 항체
|
|
US11352413B2
(en)
|
2016-05-17 |
2022-06-07 |
Albert Einstein College Of Medicine |
Engineered PD-1 variants
|
|
CN109844124B
(zh)
*
|
2016-05-20 |
2023-10-03 |
哈佛学院董事及会员团体 |
年龄相关疾病和病症的基因治疗方法
|
|
KR102543118B1
(ko)
|
2016-05-27 |
2023-06-14 |
아게누스 인코포레이티드 |
항-tim-3 항체 및 이의 사용 방법
|
|
JP7267014B2
(ja)
|
2016-06-21 |
2023-05-01 |
アイオー バイオテック エーピーエス |
癌ワクチンにおける使用のためのｐｄｌ１ペプチド
|
|
BR112019000071A2
(pt)
|
2016-07-07 |
2019-07-02 |
Bolt Biotherapeutics Inc |
conjugados adjuvantes de anticorpo
|
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
US10906957B2
(en)
*
|
2016-09-27 |
2021-02-02 |
Epicentrx, Inc. |
Immunomodulatory fusion proteins
|
|
KR20230133934A
(ko)
|
2016-10-11 |
2023-09-19 |
아게누스 인코포레이티드 |
항-lag-3 항체 및 이의 사용 방법
|
|
WO2018071837A1
(en)
*
|
2016-10-14 |
2018-04-19 |
Baylor College Of Medicine |
Radiofrequency field hyperthermia and solid tumor immunomodulation
|
|
US20190256573A1
(en)
*
|
2016-10-14 |
2019-08-22 |
Emory University |
Nanoparticles Having Molecules That Bind or Block PD-L1 and Uses In Treating Cancer
|
|
EP3538548A4
(en)
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
|
CA3041340A1
(en)
|
2016-11-09 |
2018-05-17 |
Agenus Inc. |
Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
|
|
US10780080B2
(en)
|
2016-11-23 |
2020-09-22 |
Translational Drug Development, Llc |
Benzamide and active compound compositions and methods of use
|
|
MX2019006072A
(es)
|
2016-11-30 |
2019-08-14 |
Oncomed Pharm Inc |
Metodos para tratamiento de cancer que comprenden agentes de enlace al inmunoreceptor de celulas t con dominios ige itim (tigit).
|
|
US20200078400A1
(en)
|
2016-12-03 |
2020-03-12 |
Juno Therapeutics, Inc. |
Methods for determining car-t cells dosing
|
|
WO2018106732A1
(en)
|
2016-12-05 |
2018-06-14 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
|
US11566060B2
(en)
|
2017-01-05 |
2023-01-31 |
Kahr Medical Ltd. |
PD1-CD70 fusion protein and methods of use thereof
|
|
ES2916217T3
(es)
|
2017-01-05 |
2022-06-29 |
Kahr Medical Ltd |
Una proteína de fusión SIRP1 ALPHA-41BBL y métodos de uso de la misma
|
|
DK3565579T3
(da)
*
|
2017-01-05 |
2023-09-04 |
Kahr Medical Ltd |
Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
|
|
US11299530B2
(en)
|
2017-01-05 |
2022-04-12 |
Kahr Medical Ltd. |
SIRP alpha-CD70 fusion protein and methods of use thereof
|
|
CN110198738A
(zh)
*
|
2017-01-07 |
2019-09-03 |
默克专利有限公司 |
用于靶向的TGF-β抑制的给药方案和剂型
|
|
AR110755A1
(es)
|
2017-01-20 |
2019-05-02 |
Genzyme Corp |
Anticuerpos dirigidos a hueso
|
|
TW202506185A
(zh)
|
2017-01-20 |
2025-02-16 |
法商賽諾菲公司 |
抗TGF-β抗體及其用途
|
|
WO2018144542A1
(en)
*
|
2017-02-01 |
2018-08-09 |
Acceleron Pharma Inc. |
TGFβ AND ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY
|
|
KR102642385B1
(ko)
|
2017-02-06 |
2024-03-04 |
오리오니스 바이오사이언시스 엔브이 |
표적화된 키메라 단백질 및 이의 용도
|
|
JP7244428B2
(ja)
|
2017-02-27 |
2023-03-22 |
シャタック ラボ，インコーポレイテッド |
Ｖｓｉｇ８ベースのキメラタンパク質
|
|
IL268198B2
(en)
*
|
2017-02-27 |
2024-10-01 |
Shattuck Labs Inc |
Tigit- and light-based chimeric proteins
|
|
US11267856B2
(en)
|
2017-02-27 |
2022-03-08 |
Shattuck Labs, Inc. |
CSF1R-CD40L chimeric proteins
|
|
IL268995B2
(en)
|
2017-03-02 |
2024-02-01 |
Nat Res Council Canada |
TGF-B receptor ectodomain fusion compounds and their uses
|
|
WO2018167778A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of diagnosing and prognosing cancer
|
|
WO2018167780A1
(en)
|
2017-03-12 |
2018-09-20 |
Yeda Research And Development Co. Ltd. |
Methods of prognosing and treating cancer
|
|
BR112019019973A2
(pt)
*
|
2017-03-24 |
2020-04-28 |
Orpheus Bioscience Inc |
pantlds para tratamento de transtornos autoimunes
|
|
CN107082812B
(zh)
*
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
CA3052532A1
(en)
|
2017-04-05 |
2018-10-11 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies specifically binding to pd1 and lag3
|
|
EP3612563A1
(en)
|
2017-04-19 |
2020-02-26 |
Elstar Therapeutics, Inc. |
Multispecific molecules and uses thereof
|
|
EP3615564A1
(en)
*
|
2017-04-24 |
2020-03-04 |
Alexion Pharmaceuticals, Inc. |
Antibody immune cell inhibitor fusion proteins
|
|
LT3618863T
(lt)
|
2017-05-01 |
2023-10-10 |
Agenus Inc. |
Anti-tigit antikūnai ir jų panaudojimo būdai
|
|
LT3628049T
(lt)
|
2017-05-04 |
2023-08-25 |
Acceleron Pharma Inc. |
Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai
|
|
BR112019023608A2
(pt)
|
2017-05-12 |
2020-05-26 |
Crispr Therapeutics Ag |
Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
CN110050000B
(zh)
*
|
2017-05-12 |
2022-07-26 |
苏州盛迪亚生物医药有限公司 |
含有TGF-β受体的融合蛋白及其医药用途
|
|
WO2018213297A1
(en)
|
2017-05-16 |
2018-11-22 |
Bristol-Myers Squibb Company |
Treatment of cancer with anti-gitr agonist antibodies
|
|
WO2018213747A1
(en)
*
|
2017-05-19 |
2018-11-22 |
Merrimack Pharmaceuticals, Inc. |
4-1bb agonist and cd40 agonist bispecific molecules
|
|
IL270743B2
(en)
|
2017-05-19 |
2024-09-01 |
Wuxi Biologics Shanghai Co Ltd |
Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof
|
|
US20200140547A1
(en)
*
|
2017-05-26 |
2020-05-07 |
The Johns Hopkins University |
Multifunctional antibody-ligand traps to modulate immune tolerance
|
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
|
CN110914302A
(zh)
|
2017-06-01 |
2020-03-24 |
赛托姆克斯治疗学股份有限公司 |
可活化抗pdl1抗体及其使用方法
|
|
CN107857819A
(zh)
*
|
2017-07-03 |
2018-03-30 |
江苏西迪尔生物技术有限公司 |
多功能融合蛋白及其应用
|
|
CN118126157A
(zh)
|
2017-08-03 |
2024-06-04 |
美国安进公司 |
白介素-21突变蛋白和治疗方法
|
|
KR20250020679A
(ko)
|
2017-08-04 |
2025-02-11 |
젠맵 에이/에스 |
Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도
|
|
CN107602705B
(zh)
*
|
2017-09-13 |
2018-08-31 |
北京鼎成肽源生物技术有限公司 |
一种基于蛋白互作用于检测细胞pd1表达情况的融合蛋白及其应用
|
|
KR102757384B1
(ko)
|
2017-09-27 |
2025-01-20 |
에피센트알엑스, 인코포레이티드 |
면역조절 융합 단백질
|
|
AU2018338786A1
(en)
*
|
2017-09-29 |
2020-04-16 |
Nantcell, Inc. |
Antigenic proteins and methods therefor
|
|
EP3694870A1
(en)
*
|
2017-10-10 |
2020-08-19 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
|
CN111247171A
(zh)
|
2017-10-14 |
2020-06-05 |
西托姆克斯治疗公司 |
抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
|
|
KR102742741B1
(ko)
|
2017-10-18 |
2024-12-16 |
프레시전 인코포레이티드 |
스페이서를 포함하는 폴리펩타이드 조성물
|
|
CN111315405A
(zh)
*
|
2017-11-09 |
2020-06-19 |
免疫医疗有限责任公司 |
双特异性融合多肽及其使用方法
|
|
MA51210A
(fr)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
|
WO2019113123A1
(en)
*
|
2017-12-04 |
2019-06-13 |
Precithera, Inc. |
TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
|
|
JP7348899B2
(ja)
*
|
2017-12-08 |
2023-09-21 |
マレンゴ・セラピューティクス，インコーポレーテッド |
多重特異性分子及びその使用
|
|
SG11202006148UA
(en)
|
2018-01-03 |
2020-07-29 |
Alpine Immune Sciences Inc |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
MX2020007291A
(es)
|
2018-01-12 |
2020-09-10 |
Amgen Inc |
Anticuerpos anti-pd-1 y metodos de tratamiento.
|
|
CN110151309B
(zh)
*
|
2018-02-14 |
2022-02-15 |
上海美杰医疗科技有限公司 |
多模态消融治疗术前规划方法及其设备
|
|
KR20200130709A
(ko)
|
2018-03-06 |
2020-11-19 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
전립선-특이 막 항원 car 및 이의 사용 방법
|
|
CN119431579A
(zh)
|
2018-03-09 |
2025-02-14 |
艾吉纳斯公司 |
抗cd73抗体及其使用方法
|
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
|
EP3765517A1
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
US11168138B2
(en)
*
|
2018-03-26 |
2021-11-09 |
Altor Bioscience, Llc |
Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
|
|
KR20210011919A
(ko)
|
2018-04-17 |
2021-02-02 |
셀덱스 쎄라퓨틱스, 인크. |
항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물
|
|
AU2019262139A1
(en)
*
|
2018-05-03 |
2020-11-26 |
Acceleron Pharma Inc. |
Multispecific binders of TGFβ-superfamily ligands and uses thereof
|
|
EP3788067A4
(en)
|
2018-05-03 |
2022-01-19 |
Acceleron Pharma Inc. |
NOVEL BINDERS OF TGFBETA SUPERFAMILY LIGANDS AND THEIR USES
|
|
BR112020022145A2
(pt)
*
|
2018-05-04 |
2021-01-26 |
Merck Patent Gmbh |
inibição combinada de pd-1/pd-l1, tgfbeta e dna-pk para o tratamento de câncer
|
|
US20200063100A1
(en)
|
2018-05-11 |
2020-02-27 |
Crispr Therapeutics Ag |
Methods and compositions for treating cancer
|
|
US20220089683A1
(en)
*
|
2018-06-15 |
2022-03-24 |
Acceleron Pharma Inc. |
Bi-and tri-functional fusion proteins and uses thereof
|
|
CN112368298A
(zh)
|
2018-06-22 |
2021-02-12 |
凯德药业股份有限公司 |
嵌合跨膜蛋白及其用途
|
|
JP2021529557A
(ja)
*
|
2018-06-29 |
2021-11-04 |
ジェンサン バイオファーマ、 インコーポレイテッドＧｅｎｓｕｎ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． |
抗腫瘍免疫チェックポイント調節因子アンタゴニスト
|
|
WO2020010250A2
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
CN112672753B
(zh)
*
|
2018-07-09 |
2025-07-08 |
普瑞赛格恩公司 |
融合构建体及其使用方法
|
|
CA3104780A1
(en)
|
2018-07-11 |
2020-01-16 |
Kahr Medical Ltd. |
Sirpalpha-4-1bbl variant fusion protein and methods of use thereof
|
|
IL280102B1
(en)
*
|
2018-07-11 |
2026-07-01 |
Kahr Medical Ltd |
Fusion protein containing PD1-4-1BBL and methods of using the same
|
|
EP3833391A4
(en)
|
2018-08-08 |
2022-08-10 |
Orionis Biosciences, Inc. |
ANTI-SIRP1ALPHA CHIMERIC PROTEINS AND USES THEREOF
|
|
WO2020041361A1
(en)
|
2018-08-20 |
2020-02-27 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily polypeptides
|
|
WO2020047329A1
(en)
*
|
2018-08-29 |
2020-03-05 |
Shattuck Labs, Inc. |
Chimeric proteins comprising extracellular domains and uses thereof
|
|
JP2022512540A
(ja)
|
2018-08-29 |
2022-02-07 |
シャタック ラボ，インコーポレイテッド |
Ｆｌｔ３ｌ系キメラタンパク質
|
|
CN109053895B
(zh)
|
2018-08-30 |
2020-06-09 |
中山康方生物医药有限公司 |
抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途
|
|
EP3856245A4
(en)
|
2018-09-24 |
2022-10-26 |
EyePoint Pharmaceuticals, Inc. |
MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF
|
|
JP7465272B2
(ja)
|
2018-09-27 |
2024-04-10 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
|
|
CN113302493A
(zh)
*
|
2018-10-01 |
2021-08-24 |
小利兰·斯坦福大学托管委员会 |
同时解析多种抗体同种型的高特异性和灵敏度免疫吸附诊断测定
|
|
WO2020079692A1
(en)
|
2018-10-17 |
2020-04-23 |
Biolinerx Ltd. |
Treatment of metastatic pancreatic adenocarcinoma
|
|
WO2020086741A1
(en)
*
|
2018-10-24 |
2020-04-30 |
Shire-Nps Pharmaceuticals, Inc. |
Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
|
|
MX2021005048A
(es)
|
2018-10-31 |
2021-09-08 |
Bioatla Inc |
Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
|
|
CA3117429A1
(en)
|
2018-11-01 |
2020-05-07 |
Merck Patent Gmbh |
Anti-tim-3 antibodies
|
|
AU2019372436A1
(en)
|
2018-11-01 |
2021-05-20 |
Merck Patent Gmbh |
Methods of administering anti-TIM-3 antibodies
|
|
CA3118415A1
(en)
|
2018-11-09 |
2020-05-14 |
Jiangsu Hengrui Medicine Co., Ltd. |
Tgf-.beta. receptor fusion protein pharmaceutical composition and use thereof
|
|
EP3880711A4
(en)
|
2018-11-15 |
2022-12-28 |
The General Hospital Corporation |
Agonistic tumor necrosis factor receptor superfamily polypeptides
|
|
TWI812820B
(zh)
*
|
2018-12-10 |
2023-08-21 |
美商百歐克斯賽爾治療公司 |
使用先天性免疫修飾劑及ox40促效劑治療疾病之組合療法
|
|
BR112021012631A2
(pt)
|
2018-12-26 |
2021-12-14 |
Xilio Dev Inc |
Anticorpos anti-ctla4 e métodos de uso dos mesmos
|
|
AU2020226893B2
(en)
|
2019-02-21 |
2025-02-27 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
WO2020172598A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
|
JP7579795B2
(ja)
|
2019-02-21 |
2024-11-08 |
マレンゴ・セラピューティクス，インコーポレーテッド |
ＮＫｐ３０に結合する抗体分子およびその使用
|
|
EP3937984A1
(en)
|
2019-03-15 |
2022-01-19 |
Bolt Biotherapeutics, Inc. |
Immunoconjugates targeting her2
|
|
CN114269370A
(zh)
|
2019-03-29 |
2022-04-01 |
迈斯特治疗公司 |
离体产生t细胞治疗剂的方法以及相关的组合物和方法
|
|
CA3138633A1
(en)
|
2019-04-30 |
2020-11-05 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
CN114391021B
(zh)
*
|
2019-06-21 |
2026-01-16 |
凯德药业股份有限公司 |
TGF-β受体和使用方法
|
|
ES3031566T3
(en)
|
2019-06-24 |
2025-07-09 |
Univ Stuttgart |
Tnfr2 agonists with improved stability
|
|
EP3990116A1
(en)
|
2019-06-28 |
2022-05-04 |
Gensun Biopharma Inc. |
ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
|
|
BR112022000319A2
(pt)
*
|
2019-07-11 |
2022-03-15 |
Kahr Medical Ltd |
Heterodímeros e métodos de uso dos mesmos
|
|
EP3999527A4
(en)
*
|
2019-07-18 |
2024-04-17 |
Memorial Sloan Kettering Cancer Center |
METHODS AND COMPOSITIONS FOR TARGETING TGF-BETA SIGNALIZING IN CD4+ HELPER T CELLS FOR CANCER IMMUNOTHERAPY
|
|
WO2021025140A1
(ja)
*
|
2019-08-08 |
2021-02-11 |
小野薬品工業株式会社 |
二重特異性タンパク質
|
|
WO2021041886A1
(en)
*
|
2019-08-29 |
2021-03-04 |
Nantbio, Inc. |
Modified n-810 and methods therefor
|
|
CN114072428B
(zh)
*
|
2019-08-30 |
2024-02-13 |
正大天晴药业集团南京顺欣制药有限公司 |
一种靶向PD-L1和TGF-β的融合蛋白及其用途
|
|
KR20210033436A
(ko)
*
|
2019-09-18 |
2021-03-26 |
주식회사 에스엘바이젠 |
신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도
|
|
CN110734498A
(zh)
*
|
2019-10-15 |
2020-01-31 |
上海科棋药业科技有限公司 |
一种用于解除免疫抑制的融合蛋白及其应用
|
|
JP7495489B2
(ja)
*
|
2019-10-21 |
2024-06-04 |
ナンチン リーズ バイオラブス カンパニー，リミティド |
ＰＤ－１およびＴＧＦβを標的化する組換えタンパク質
|
|
FI4034170T3
(fi)
|
2019-10-23 |
2026-04-16 |
Cue Biopharma Inc |
Tgf-beta-polypeptidejä
|
|
TW202128763A
(zh)
*
|
2019-11-12 |
2021-08-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
含有ＴＧＦ－β受體的融合蛋白及其醫藥用途
|
|
AU2020382219A1
(en)
|
2019-11-13 |
2022-05-12 |
Crispr Therapeutics Ag |
Manufacturing process for making T cells expressing chimeric antigen receptors
|
|
IL293350A
(en)
|
2019-11-27 |
2022-07-01 |
Myst Therapeutics Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
|
US12516133B2
(en)
|
2019-11-27 |
2026-01-06 |
Shanghai Epimab Biotherapeutics Co., Ltd |
TGFβ/PD-L1 bispecific binding proteins
|
|
CN113004414B
(zh)
*
|
2019-12-20 |
2022-09-06 |
广东菲鹏制药股份有限公司 |
抗PD1和TGFβ的双功能抗体及其制备方法，以及含有其的药物组合物
|
|
CN113121699A
(zh)
*
|
2019-12-30 |
2021-07-16 |
国典(北京)医药科技有限公司 |
Pttrap1双特异性融合蛋白及其应用
|
|
EP4084821A4
(en)
|
2020-01-03 |
2024-04-24 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
|
WO2021138474A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
US20230123454A1
(en)
*
|
2020-01-23 |
2023-04-20 |
Genexine, Inc. |
Fusion protein comprising pd-l1 protein and use thereof
|
|
US11912751B2
(en)
*
|
2020-01-31 |
2024-02-27 |
Globetek Science Foundation |
Bi-functional fusion proteins comprised of TGF-B and immune checkpoint domains
|
|
CA3170828A1
(en)
|
2020-02-13 |
2021-08-19 |
Lawrence Livermore National Security, Llc |
Methods of sequestering target elements
|
|
EP4110799B1
(en)
|
2020-02-27 |
2024-11-06 |
Turnstone Biologics Corp. |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
|
CN115708411A
(zh)
*
|
2020-04-16 |
2023-02-21 |
南通壹宸生物医药科技有限公司 |
一种pd-1突变体多肽及其制备和用途
|
|
AU2021261420A1
(en)
|
2020-04-24 |
2022-12-01 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
|
WO2021218883A1
(zh)
*
|
2020-04-28 |
2021-11-04 |
神州细胞工程有限公司 |
一种TGFβR2胞外区截短分子、其与抗EGFR抗体的融合蛋白及其抗肿瘤用途
|
|
US12202882B2
(en)
|
2020-05-08 |
2025-01-21 |
Alpine Immune Sciences, Inc. |
APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof
|
|
CN111690070A
(zh)
*
|
2020-05-13 |
2020-09-22 |
深圳市众循精准医学研究院 |
一种sPD-1-Fc-sTGFβRII融合蛋白及其应用
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
US12194094B2
(en)
|
2020-07-10 |
2025-01-14 |
Precigen, Inc. |
Fusion constructs and methods of using thereof
|
|
AU2021331075A1
(en)
|
2020-08-26 |
2023-04-06 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
CA3190573A1
(en)
|
2020-08-26 |
2022-03-03 |
Andreas Loew |
Methods of detecting trbc1 or trbc2
|
|
JP2023539645A
(ja)
|
2020-08-26 |
2023-09-15 |
マレンゴ・セラピューティクス，インコーポレーテッド |
Ｎｋｐ３０に結合する抗体分子およびその使用
|
|
WO2022057061A1
(en)
*
|
2020-09-16 |
2022-03-24 |
Suzhou Neologics Bioscience Co., Ltd. |
Pd-l1 antibodies, fusion proteins, and uses thereof
|
|
AU2021365528A1
(en)
*
|
2020-10-23 |
2023-06-15 |
Hq Han |
Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof
|
|
CA3197104A1
(en)
*
|
2020-11-11 |
2022-05-19 |
Hq Han |
Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof
|
|
CN114539415B
(zh)
*
|
2020-11-24 |
2024-02-02 |
普米斯生物技术(珠海)有限公司 |
一种抗PD-L1/VEGF/TGF-β多特异性抗体及其用途
|
|
CA3202867A1
(en)
*
|
2020-12-15 |
2022-06-23 |
Bicara Therapeutics Inc. |
Pharmaceutical formulations for fusion proteins
|
|
CN116940592A
(zh)
*
|
2020-12-15 |
2023-10-24 |
比卡拉治疗股份有限公司 |
用于治疗癌症的组合疗法
|
|
CN117120075A
(zh)
*
|
2021-02-17 |
2023-11-24 |
库拉治疗股份有限公司 |
抗病原体白细胞介素-TGF-β受体融合多肽
|
|
WO2022192236A1
(en)
*
|
2021-03-08 |
2022-09-15 |
Shattuck Labs, Inc. |
Chimeric proteins in autoimmunity
|
|
CA3217279A1
(en)
|
2021-05-04 |
2022-11-10 |
Olga Ignatovich |
Anti-tigit antibodies and methods of use thereof
|
|
AR125753A1
(es)
|
2021-05-04 |
2023-08-09 |
Agenus Inc |
Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
|
|
KR20240017937A
(ko)
*
|
2021-06-07 |
2024-02-08 |
플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 |
치료제의 표적화된 전달을 위한 조성물 및 방법
|
|
WO2022261061A1
(en)
|
2021-06-08 |
2022-12-15 |
Kite Pharma, Inc. |
Gpc3 binding molecules
|
|
US20240382563A1
(en)
*
|
2021-07-21 |
2024-11-21 |
Mayo Foundation For Medical Education And Research |
Promoting immune surveillance against cancer cells
|
|
CA3230292A1
(en)
*
|
2021-08-27 |
2023-03-02 |
Theranotics Co., Ltd. |
Bispecific molecule specifically binding to b7-h3 and tgfb and uses thereof
|
|
KR20230044130A
(ko)
*
|
2021-09-24 |
2023-04-03 |
바이오엔시스템스 주식회사 |
Pd-1 및 il-21을 포함하는 융합단백질 이량체 및 이의 용도
|
|
CN118574847A
(zh)
|
2021-10-11 |
2024-08-30 |
Y-Trap 公司 |
抑制il-23信号传导的组合物和方法
|
|
US12559576B2
(en)
*
|
2021-11-11 |
2026-02-24 |
Regeneron Pharmaceuticals, Inc. |
CD20-PD1 binding molecules and methods of use thereof
|
|
AU2022435471A1
(en)
*
|
2022-01-18 |
2024-05-30 |
Fbd Biologics Limited |
Cd47/pd-l1-targeting protein complex and methods of use thereof
|
|
US20230348561A1
(en)
*
|
2022-04-28 |
2023-11-02 |
Immatics US, Inc. |
Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
|
|
CA3260155A1
(en)
*
|
2022-06-29 |
2024-01-04 |
Cdres Pharma Llc |
Immunologically active polypeptide
|
|
EP4695302A2
(en)
*
|
2023-04-11 |
2026-02-18 |
Flagship Pioneering Innovations VII, LLC |
Compositions and methods
|
|
WO2024245380A1
(en)
*
|
2023-05-31 |
2024-12-05 |
Fbd Biologics Limited |
Cd47/pd-l1-targeting protein complex and methods of use thereof
|
|
CN116514913B
(zh)
*
|
2023-06-07 |
2025-03-21 |
澳门大学 |
具有抗肿瘤活性的tnfr2靶向肽及其应用
|
|
WO2025006456A2
(en)
*
|
2023-06-26 |
2025-01-02 |
Protect Biotech Incorporation |
Compositions and methods for treating cancer
|